Results 181 to 190 of about 3,468,016 (309)

Enhancing cancer vaccine efficacy via electrostatic engineering of an FcγR-targeted protein. [PDF]

Front Immunol
Wu CC, Chen CL, Chiang CY, Tu LL, Liu SJ, Leng CH, Chen HW.   +6 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Reversal of T cell exhaustion enables cancer vaccine efficacy in <i>BRCA1</i>-deficient ovarian cancer. [PDF]

iScience
Beziaud L, Minasyan A, Chiang CL, Soukarieh RM, Coppi MM, Rovelli R, Thevenet J, Tissot S, Dangaj-Laniti D, Kandalaft LE.   +9 more
europepmc   +1 more source

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

British Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis, Christine Leopold, Joyce M. Hoek, Raymond M. Schiffelers, Marie L. De Bruin   +4 more
wiley   +1 more source

Mapping the cancer vaccine landscape. [PDF]

J Immunother Cancer
Hu F, Li H, Lv W, Li M, Gale RP, Huang X, Liang Y.   +6 more
europepmc   +1 more source

Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland. Methods The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024.
Tanja Mueller, Christine Crearie, Liya Lu, Jiafeng Pan, Fraser N. Sneden, David Martin, Amanj Kurdi, Catherine S. Thomson, Julie Clarke, Marion Bennie   +9 more
wiley   +1 more source

Immunoinformatic insights for design and clinical prospects of pan-RAS cancer vaccine. [PDF]

Front Med (Lausanne)
Srivastava R, Rana TRK.
europepmc   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Cancer Vaccine Targeting Mutated GNAQ-Expressing Uveal Melanoma. [PDF]

Cancers (Basel)
Alexeev V, Terai M, Koshkin S, Igoucheva O, Sato T.   +4 more
europepmc   +1 more source

Inventory Replenishment and Transshipment for Distributed Autologous Cell Therapy Manufacturing Networks

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Autologous cell therapy (AuCT) manufacturing networks must balance two competing objectives: reducing cost and improving patient access to time‐sensitive therapy. This study compares three AuCT manufacturing network designs: a centralized network with a single manufacturing facility, a coordinated point‐of‐care (POC) network in which POCs can ...
Zhaowei Li, Chelsea C. White III, Kan Wang, Ben Wang   +3 more
wiley   +1 more source